Several antibodies have been developed for T cell NHL (e.g., alemtuzumab (anti-CD52), brentuximab (anti-CD30), and mogalizumab (anti-CXCR4)), all of which mediate at least part of their anti-lymphoma efficacy through ADCC. This evidence concerns the gene CXCR4 and T-cell non-Hodgkin lymphoma.